• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    test company saurabh

    Almac Group

    Baxter BioPharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Emergent BioSolutions

    Aphena Pharma Solutions

    Adare Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Contract BioManufacturing in China: Creating a New Segment

    An up-close look at China’s growing market for CMO services.

    Contract BioManufacturing in China: Creating a New Segment
    Contract BioManufacturing in China: Creating a New Segment
    Figure 1: Country Selections as Destination for International Outsourcing of BioManufacturing (All Respondents)
    Related CONTENT
    • Vetter continues its successful performance at the 2021 CMO Leadership Awards
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Argonaut Opens Custom Controls and Standards Facility
    • Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    Vicky Qing Xia and Leo Cai Yang, BioPlan Associates04.10.18
    The number and size of contract manufacturing organizations (CMOs) in China are expanding for three key reasons. The main reason is that there are more biosimilars and innovative drugs entering the clinical pipeline, and reaching commercial scale. Also, because most early-stage biologics developers in China lack manufacturing facilities, the need for contract manufacturing services is growing. The second reason is the shift in regulatory policy allowing contract manufacturing in the first place (see below about the Marketing Authorization Holder (MAH) system reforms). The third is economic—China is demonstrating clear investment interest in participating in global markets for both innovative biologics and biosimilars produced at GMP quality levels. These factors are creating a strong market environment for CMO services.

    As part of this market environment, we are also seeing China’s biomanufacturing facilities actively expanding their facilities. In fact, total capacity in China has grown by over 10%, based on our analysis of facilities under active construction. BioPlan’s Top 60 Biopharmaceutical Manufacturers in China1 directory shows continued capacity expansions and upgrades at a majority of bio-manufacturer facilities through 2017. This is contributing to an increasingly robust China-bio ecosystem.

    CMOs in China before 2016
    Before 2016, pharmaceutical contract manufacturing for domestic drugs essentially did not exist in China due to a regulatory framework that demanded drug-developers be in charge of the manufacturing of the drug products they developed, i.e., no third-party/CMO manufacturing for either clinical trials or commercial production in China. Meanwhile, manufacturing for certain developing overseas markets remained largely unregulated, and this is where most Chinese CMOs generated most of their export revenue (pre-2016).

    However, as a result of these efforts, some contract manufacturers have been growing; at the time, most were focused on small molecule therapeutics, especially active pharmaceutical ingredient (API) and intermediate products. A few players also established FDA-certified contract manufacturing of finished-dosage chemical drugs, for example, Hangzhou Minsheng Pharma. CMOs for biological therapeutics, especially for mammalian cell systems, require a much more sophisticated production capability, and few domestic companies had the process development, technical, or quality systems capabilities. A few very well-known contract research organizations (CROs) with scientist backgrounds, such as WuXi AppTec and Chempartner, developed divisions devoted to contract bio-manufacturing for their overseas clients. Yet more often than not, these facilities were lab-scale or pilot-scale producing biologicals for preclinical or clinical trial use. The Beijing-based Autekbio, founded in 2011, was the first, and one of the few CMOs fully devoted to contract manufacturing of biologicals.

    Opportunities for China-based biological CMOs
    Though China’s contract biomanufacturing is a relatively very young business, and it remains constrained by regulatory hurdles, recent years have seen a wave of opportunities. With the gradual maturing of bioprocessing, multi-national pharma companies have been faced with the question as to whether bioprocessing should remain a core competence for big pharmaceutical companies.

    The fast growth of global biopharma markets has also resulted in increased R&D investment in biologics and a higher demand for a variety of outsourcing options, including biologic product manufacturing. In China, as elsewhere, development of a new biotherapeutic is a very capital intensive and establishment of GMP grade manufacturing facilities requires tremendous time, capital and technology. Though multinational pharmaceutical companies usually have their own GMP manufacturing facilities elsewhere, they still focus on ways to reduce costs. 

    One strategy is outsourcing manufacturing of relatively old biopharmaceutics such as insulin, interferon, interleukin, or growth hormones, to a CMO and utilize their own facilities for newer and more valuable biological pipeline. In some cases, collaboration with a manufacturing partner in another country, such as China, can bring cost advantages and preferential treatment in drug evaluation and approval processes.

    At smaller scales, contract manufacturing is almost indispensable for small to medium sized biotechs, which are usually cash-strapped and do not have the financial resources to complete their own GMP grade manufacturing facilities. With support from venture capitalists, the financial resources are available to purchase services from external vendors.
    This process is clearly developing in China as CMOs are now beginning to service smaller biotechs so they can concentrate on their R&D efforts. As a result, outsourcing in China at clinical scale has grown. According to BioPlan’s research on China biopharmaceuticals2 the global biopharmaceutical outsourcing service market will grow faster than in Western markets, at nearly 20% over the next three or four years. CMO services in China are likely to continue to expand, as clinical scale biologics in the pipeline produced for smaller companies by CMOs come to represent an increasing proportion of the biopharmaceuticals on the Chinese market in coming years. 

    This new wave of outsourcing may benefit CMOs in multiple Asian countries, including Singapore, South Korea, India and China. Many see growth opportunities in this sector. For example, Samsung Biologics, founded in 2011, with its massive mammalian cell capacity (360,000L), surpasses most established service providers. Singapore is also a hot spot favored by many global companies considering outsourcing of bioprocessing. Some industry insiders in China strongly believe that China can be as good a destination for this wave of outsourcing. Among them is Li Zhiliang, chief executive officer, Autekbio, who projects that outsourcing of bioprocessing will become a global standard, and ‘made-in-China’ biopharmaceuticals will be as commonplace as ‘made-in-China’ iPhones.

    Domestic Chinese biopharma creating demand for services
    Development of biological pipelines by domestic Chinese companies represents a significant portion of the R&D by small biopharmaceutical companies. The private and public funding for these companies is also driving the need for domestic CMOs. China, especially in the Yangtz Delta Region, is now home to hundreds of start-up bio companies trying to develop pipelines in biologics.

    According to Bioplan’s recent research for its Top 60 Biopharmaceutical Facilities in China Directory, there are well over 60 biopharma companies in China, both new and old, that have started mAb development projects. Luo Jiali, chief executive officer of Boehringer Ingelheim’s contract manufacturing facility for biologics in China, said that since the successful launch of Langmu in 2013, Chinese developers have submitted IND applications for 109 Class I biological therapeutics, including 61 therapeutic mAb, 9 ADC, 4 bi-specific antibody and 1 PD-L1-Fc, as well as 26 recombinant proteins, 13 fusion proteins and a number of gene therapy products, therapeutic vaccines and oncolytic viruses.2 It may well be that the many relatively new biotech companies in China will need the support from external manufacturing partners, and this may create the critical mass needed to establish GMP grade contract bioprocessing facilities. 

    Regulatory reforms in China to capture outsourcing opportunities
    With both global and domestic demand on the rise, Chinese regulatory authorities made the move to permit contract bio-manufacturing in China in 2016. That year, China started the pilot Market Authorization Holder (MAH) program, under which holders of a CFDA biologics approval number now have the option to either manufacture the drugs or use a CMO. The MAH breakthrough is a pilot running in 10 provinces and municipalities, and then in 2018, it is expected to be applied to the whole country. It is widely expected that the regulatory hurdles for contract manufacturing of drugs in China will shortly be removed.

    The MAH reform is already boosting China’s contract manufacturing industry. According to statistics from Liberation Daily, through May 2017 there were a total of 381 applications of MAH and Shanghai alone saw 16 applicants of MAH for 24 drug projects with 18 CMO partners. This is likely good news for Boehringer Ingelheim, the first multinational biologics CMO in China, and the company that has been in the middle of the lobbying efforts for MAH reform. The company announced that even before it officially started operation in 2017, demand for services have been booked into 2019. Biotech companies, including NASDAQ-listed BeiGene and newly founded Zai-Lab, have signed agreements with Boehringer Ingelheim under which it will provide process optimization and manufacturing services in its Shanghai facility for their new monoclonal antibodies. 

    Quite a few domestic pharma companies, including North China Pharma and Tasly Pharma, also stated that they have idle capacity available for contract manufacturing.3 Autek’s Mr. Li said that at its current stage China has over 50% idle capacity in bio-manufacturing compared to 30% in the U.S. EU. He expects the implementation of MAH is going to significantly decrease idle capacity, leading to a cost reduction and increased productivity. 

    Drug makers’ concern about capacity
    There is no doubt that MAH reform is good news for China’s CMO industry. But even still, a majority of domestic mid-scale and larger biopharma developers may not be planning to outsource manufacturing. BioPlan’s analyses of China’s biopharma facilities show that over 90% of mid-scale and larger biopharmas are planning to build or expand their own facilities. For example, BeiGene, the company using Boehringer’s CMO services in Beijing, is also building a bio-manufacturing facility in Guangzhou. Major concerns about using CMOs are no different from those in the West, including quality issues, loss of control, need for reliability, lack of commercial insurance to cover risk sharing, as well lack of experience in manufacturing partnership management and auditing. 

    Things in China are clearly in transition, and drug developers, who are responsible for drug safety/quality, must learn to monitor their contract manufacturing partners. Small biotechs with only a few dozen staff, will have challenges doing so. Some in China believe that commercial insurance may be necessary in case of drug quality issues, and at least one commercial insurance company has expressed interest. Industry insiders have also expressed concerns over how to clearly define the partner roles and responsibility under MAH mandates. This evolution of contract manufacturing in China has parallels in the U.S. and EU, but China has the benefit of regulatory and contractual models that have worked in other regions.

    Global outsourcing destinations: China on the radar
    In our 14th Annual Report and Survey of Biopharmaceutical Manufacturing,4 we asked global respondents to consider their five-year time horizon leading up to 2022, and to evaluate their facility’s current plans for future international capacity expansion (not domestic). We identified more than 25 countries as potential outsourcing destinations. Among all respondents, the U.S. continues to rank highest as a potential outsourcing destination, with 30.9% indicating that there was a “Likelihood” or “Strong likelihood” that they would offshore production to facilities there over the next five years. Following the U.S. were Ireland and India, but for the first time, China beat out Germany and Singapore for fourth place (see Figure 1 in the slider above). We note that among respondents, patent and IP issues also come into play and these have likely increased as government policies and concerns over hacking continue to make news.

    Looking into the future
    China’s CMO business is young and still in the developmental stage, but indications suggest that when legal restrictions are removed, demand will slowly increase as the segment gains experience and knowledge. Industry concentration in biopharma will be relatively high compared to small molecule pharmaceutical contract manufacturing, where there are a greater number of established companies.

    In biopharma, clearly there are already dominant players. Wuxi Biologics, which has gone through a very successful IPO on the Hong Kong stock exchange, just started operation of a new facility, which is the largest mammalian cell culture manufacturing facility fully using disposable bioreactors in the world. The facility uses 14x 2,000L and two 1,000L disposable bioreactors for late-phase clinical and commercial manufacturing. It is also the largest biologics manufacturing facility of any kind in China.

    JHL Biotech’s Wuhan facility, which started operations in 2016, has a current capacity of ~10,000L and is also expanding. 3S Guojian, which successfully launched the first made-in-China mAb therapeutics in China, also uses its idle capacity for contract manufacturing and has developed a good reputation in the industry.

    New CMOs have started operations since 2016, but it is likely that China’s biopharma CMO segment will continue to be dominated by several larger players as they build solid reputations in the industry. And in biopharma, where product quality and safety is everything, that will create a high hurdle for new entrants. We also expect the quality standards for manufacturing to rise as CMOs, whose businesses depend on multiple products/services contracts with multiple drug developers, put great effort into ensuring impeccable manufacturing operations. In this industry, one failure can ruin a company’s reputation, whether in China or elsewhere.

    This rising manufacturing standard is also likely to bring good news to vendors of new bioprocessing technologies, products and service. We have already witnessed the spread of single use technology in China’s biopharma industry and CMOs played a significant role. Some optimistic observers might even project that CMOs may transform China’s biopharma industry as outsourcing becomes a mainstream solution, enabling pharma companies to concentrate on development of innovative drugs. 

    References
    1. Top 60 Biopharmaceutical Facilities in China, BioPlan Associates, Inc., Rockville, MD USA, March2017; www.bioplanassociates.com updated Feb 2018
    2. Advances in Biopharmaceuticals in China, 2nd Edition, To be released Summer 2018, BioPlan Associates, Inc. www.bioplanassociates.com
    3. Pharma Economics, MAH, 2016-6-15
    4. 14th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, April 2017, BioPlan Associates, Inc., www.bioplanassociates.com

    Vicky Qing Xia is project director at BioPlan Associates. She has experience in consulting, business development, as well as alliance management in China’s biopharmaceutical industry. Her expertise includes developing research and analysis on multiple global market segments, and has managed a team of industry experts, and
    projects. Contact: +1 301-921-5979; www.bioplanassociates.com.

    Cai Yang is project manager at BioPlan Associates. He has business development experience in biotech and pharma segments and 10 years in market research and has worked with equipment manufacturers in pharmaceutical and medical device industries in Switzerland, Austria and Germany. He has also project managed studies involving new biopharmaceutical technology applications in China including analysis and strategy development.
    Related Searches
    • singapore
    • fda
    • API
    • GMP
    Suggested For You
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Argonaut Opens Custom Controls and Standards Facility Argonaut Opens Custom Controls and Standards Facility
    Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
    Thermo Fisher Buys Novasep Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Baxter, Novavax Ink Sterile Manufacturing Agreement Baxter, Novavax Ink Sterile Manufacturing Agreement
    Fujifilm to Invest $40M in New Facility Fujifilm to Invest $40M in New Facility
    Sesen Bio Enters Mfg. and Supply Partnership with Qilu Pharma Sesen Bio Enters Mfg. and Supply Partnership with Qilu Pharma
    Life Science Success Podcast: Matt Hicks Life Science Success Podcast: Matt Hicks
    Baxter Invests $50M to Expand Sterile Fill/Finish Manufacturing Operations Baxter Invests $50M to Expand Sterile Fill/Finish Manufacturing Operations
    Samsung Biologics Samsung Biologics
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    Ensuring Quality During the Transfer and Scale Up of Rx Drugs Ensuring Quality During the Transfer and Scale Up of Rx Drugs

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20


    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20

    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20


    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20

    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers
    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Coatings World

    Latest Breaking News From Coatings World

    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Inahsi Naturals Achieves EU Compliance
    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Happi

    Latest Breaking News From Happi

    Clean Beauty Collective Supports EarthDay.org
    Freckle Pens Are Spot On!
    The Detox Market Partners with Good Face Project
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UFlex adds capacity in packaging films
    CEC expands into labels and packaging with Heidelberg
    ABG delivers Digicon Series 3 to UK printer
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login